Our AF combination therapy may prevent/attenuate postsurgical intra-abdominal adhesion formation via targeting two important factors – remesothelialization and inflammation through recruiting CD133 stem cells and HGF producing M2 macrophages. This evidence concerns the gene PROM1 and atrial fibrillation.